TORONTO, ONTARIO: TTI-621 Phase I clinical trial progressing according to plans Completed acquisition and integration of Fluorinov Cash amounted to $65.8 million as of March 31, 2016
...
DUBLIN, IRELAND: Presentation to Highlight HABP/VABP Patient Populations, Including Those With MRSA, for Which VIBATIV May Serve as an Appropriate Treatment
...
LEXINGTON, MA: Company to Provide Corporate Update and First Quarter Financial Results Announcement of the Second Positive Phase II Clinical Trial of NS2 in 2016 NS2 Has Now Demonstrated Clinical Activity in the Two ...
Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.